Segall Bryant & Hamill LLC decreased its holdings in shares of Plexus Corp. (NASDAQ:PLXS - Free Report) by 31.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 168,169 shares of the technology company's stock after selling 75,443 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.62% of Plexus worth $22,990,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Quest Partners LLC grew its stake in shares of Plexus by 36,700.0% during the second quarter. Quest Partners LLC now owns 368 shares of the technology company's stock worth $38,000 after acquiring an additional 367 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Plexus by 89.4% during the third quarter. Farther Finance Advisors LLC now owns 464 shares of the technology company's stock worth $63,000 after acquiring an additional 219 shares during the last quarter. Innealta Capital LLC purchased a new stake in shares of Plexus during the second quarter worth about $51,000. GAMMA Investing LLC grew its stake in shares of Plexus by 190.1% during the third quarter. GAMMA Investing LLC now owns 760 shares of the technology company's stock worth $104,000 after acquiring an additional 498 shares during the last quarter. Finally, EntryPoint Capital LLC grew its stake in shares of Plexus by 56.2% during the first quarter. EntryPoint Capital LLC now owns 976 shares of the technology company's stock worth $93,000 after acquiring an additional 351 shares during the last quarter. Hedge funds and other institutional investors own 94.45% of the company's stock.
Plexus Stock Performance
NASDAQ:PLXS traded down $2.08 during trading hours on Wednesday, reaching $155.75. The company had a trading volume of 54,622 shares, compared to its average volume of 132,441. Plexus Corp. has a 1-year low of $90.18 and a 1-year high of $169.41. The firm has a market cap of $4.24 billion, a PE ratio of 39.36 and a beta of 0.87. The business's 50 day moving average price is $140.92 and its 200-day moving average price is $123.18. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.51 and a quick ratio of 0.71.
Plexus (NASDAQ:PLXS - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The technology company reported $1.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.55 by $0.30. Plexus had a return on equity of 9.51% and a net margin of 2.82%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the company posted $1.44 earnings per share. Plexus's revenue for the quarter was up 2.6% on a year-over-year basis. Research analysts forecast that Plexus Corp. will post 6.13 EPS for the current year.
Insider Transactions at Plexus
In other news, insider Victor (Pang Hau) Tan sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $127.50, for a total transaction of $127,500.00. Following the completion of the transaction, the insider now directly owns 8,605 shares of the company's stock, valued at $1,097,137.50. This represents a 10.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Karen Marie Rapp sold 500 shares of the company's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $128.02, for a total value of $64,010.00. Following the transaction, the director now directly owns 9,586 shares of the company's stock, valued at approximately $1,227,199.72. The trade was a 4.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,552 shares of company stock valued at $5,250,872 in the last three months. 2.39% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. Benchmark upped their target price on Plexus from $150.00 to $165.00 and gave the company a "buy" rating in a research report on Monday, October 28th. StockNews.com upgraded Plexus from a "hold" rating to a "buy" rating in a research report on Monday. KeyCorp assumed coverage on Plexus in a research report on Tuesday, October 22nd. They issued a "sector weight" rating on the stock. Finally, Needham & Company LLC upped their target price on Plexus from $144.00 to $162.00 and gave the company a "buy" rating in a research report on Friday, October 25th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Plexus currently has an average rating of "Moderate Buy" and a consensus price target of $133.50.
Get Our Latest Analysis on Plexus
Plexus Company Profile
(
Free Report)
Plexus Corp. provides electronic manufacturing services in the United States and internationally. It offers design, develop, supply chain, new product introduction, and manufacturing solutions, as well as sustaining services to companies in the healthcare/life sciences, industrial/commercial, aerospace/defense, and communications market sectors.
Recommended Stories
Before you consider Plexus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Plexus wasn't on the list.
While Plexus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.